Dysregulated Expression and Methylation Analysis Identified TLX1NB as a Novel Recurrence Marker in Low-Grade Gliomas.

Hongzhou Duan,Zuozhen Yang,Jiayong Zhang,Yingjin Wang,Changwei Yuan,Shengli Shen,Chen Li,Xingshun Xu

doi:10.1155/2020/5069204

Abstract

Low-grade gliomas (LGGs) are the most common CNS tumors, and the main therapy for LGGs is complete surgical resection, due to its curative effect. However, LGG recurrence occurs frequently. Biomarkers play a crucial role in evaluating the recurrence and prognosis of LGGs. Numerous studies have focused on LGG prognosis. However, the multiomics research investigating the roles played by gene methylation and expression in LGG recurrence remains limited. In this study, we integrated the TCGA and GEO datasets, analyzing RNA and methylation data for recurrence (R) and nonrecurrence (NR) groups. We found a low expression of TLX1NB and high methylation in recurrence patients. Low expression of TLX1NB is associated with poor survival (OS: p = 0.04). The expression of TLX1NB is likely to play a role in the prognosis of LGG. Therefore, TLX1NB may represent an alternative early biomarker for the recurrence of low-grade gliomas.

Highlights

Low-grade glioma (LGG) is an uncommon type of the primary central nervous system tumor classified by the WHO as Class I and II [1, 2]
RNA read count data, expression matrix data, copy number variation data, and DNA methylation data (Illumina Human Methylation 450 k Array) of LGG were obtained from The Cancer Genome Atlas (TCGA, https:// cancergenome.nih.gov)
Through Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) functional analyses, the differentially expressed genes were determined to be primarily involved in neuroactive ligand−receptor interaction pathways (Figure 1(b)) and DNA-binding transcription activator activity (Figure 1(c))

Summary

Introduction

Low-grade glioma (LGG) is an uncommon type of the primary central nervous system tumor classified by the WHO as Class I and II [1, 2]. LGG is inactive, and the main therapy strategy is complete surgical resection because this treatment can be curative. Due to recurrence and metastasis, the prognosis of LGG remains controversial [7, 8]. Because these tumors have a long asymptomatic natural history, whether patients with limited lesions and few symptoms are given active or delayed treatment and the timing of postoperative radiotherapy and chemotherapy have not been determined [9]. It is of great importance to understand the underlying molecular mechanisms governing LGG recurrence and to identify novel recurrenceassociated biomarkers [5, 10]

Objectives

Methods

Results

Conclusion